Chemomab Therapeutics Advances Phase 3 Plans for Nebokitug
I'm PortAI, I can summarize articles.
Chemomab Therapeutics Ltd. is advancing its Phase 3 plans for nebokitug, a monoclonal antibody targeting CCL24, aimed at treating primary sclerosing cholangitis (PSC). The company reported a cash position of $9.5 million, sufficient to fund operations through mid-2026. R&D expenses decreased to $1.3 million, while general and administrative expenses rose to $1.0 million. The net loss for the quarter was $2.1 million. Chemomab is also enhancing its intellectual property with new patents and plans a one-for-four reverse split to strengthen its market position.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments